Clinical Trial

CS-101 in Patients With β-thalassemia

Enrolling by Invitation Early Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated June 9, 2026 (before its estimated July 31, 2026 completion). Its status may not reflect the trial's current state.
Summary
The goal of this open label, single-arm clinical study is to learn about the safety and efficacy of CS-101 in treating β-thalassemia.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2024-03-19; most recent amendment 2026-06-05.
Status change: Recruiting → Enrolling by Invitation 2024-05-05
Status change: Not Yet Recruiting → Recruiting 2024-04-30
Trial Details
NCT Number NCT06328764
Lead Sponsor CorrectSequence Therapeutics Co., Ltd
Collaborators: First Affiliated Hospital of Guangxi Medical University
Conditions Beta-Thalassemia
Enrollment 10 participants
Start Date 2024-03-19
Primary Completion 2026-07-31 (estimated)
Study Completion 2026-07-31 (estimated)
Updated on ClinicalTrials.gov 2026-06-09